Literature DB >> 24790678

Teriflunomide - a new oral agent for multiple sclerosis treatment.

Florina Antochi1.   

Abstract

Entities:  

Year:  2013        PMID： 24790678      PMCID： PMC3968482     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN： 1841-9038


× No keyword cloud information.
  3 in total

1.  A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

Authors:  P W O'Connor; D Li; M S Freedman; A Bar-Or; G P A Rice; C Confavreux; D W Paty; J A Stewart; R Scheyer
Journal:  Neurology       Date:  2006-03-28       Impact factor: 9.910

2.  Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

Authors:  Paul O'Connor; Jerry S Wolinsky; Christian Confavreux; Giancarlo Comi; Ludwig Kappos; Tomas P Olsson; Hadj Benzerdjeb; Philippe Truffinet; Lin Wang; Aaron Miller; Mark S Freedman
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

3.  Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.

Authors:  Christian Confavreux; David K Li; Mark S Freedman; Philippe Truffinet; Hadj Benzerdjeb; Dazhe Wang; Amit Bar-Or; Anthony L Traboulsee; Lucy E Reiman; Paul W O'Connor
Journal:  Mult Scler       Date:  2012-02-03       Impact factor: 6.312
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.